18β-Glycyrrhetinic acid inhibits periodontitis via glucocorticoid-independent nuclear factor-ΚB inactivation in interleukin-10-deficient mice

Journal of Periodontal Research

Volumn 45, Issue 6, 2010, Pages 757-763

  Sasaki, H ^a   Suzuki, N ^b   AlShwaimi, E ^c   Xu, Y ^d   Battaglino, R ^a   Morse, L ^e   Stashenko, P ^a  

^a FORSYTH INSTITUTE   (United States)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^d KUNMING MEDICAL UNIVERSITY   (China)

^e and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

Author keywords

18 glycyrrhetinic acid; Interleukin 10 deficient mouse; Nuclear factor B; Periodontal disease

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 18ALPHA GLYCYRRHETINIC ACID; 18ALPHA-GLYCYRRHETINIC ACID; DRUG DERIVATIVE; GLUCOCORTICOID; GLYCYRRHETINIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10;

ALVEOLAR BONE LOSS; ANIMAL; ARTICLE; C57BL MOUSE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; GERMFREE ANIMAL; MACROPHAGE; MICROBIOLOGY; MOUSE; MOUSE MUTANT; OSTEOCLAST; PERIODONTITIS; PHOSPHORYLATION; PORPHYROMONAS GINGIVALIS; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

11-BETA-HYDROXYSTEROID DEHYDROGENASES; ALVEOLAR BONE LOSS; ANIMALS; CELL PROLIFERATION; GENE EXPRESSION; GLUCOCORTICOIDS; GLYCYRRHETINIC ACID; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-10; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; OSTEOCLASTS; PERIODONTITIS; PHOSPHORYLATION; PORPHYROMONAS GINGIVALIS; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES;

EID: 77958568362     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/j.1600-0765.2010.01296.x     Document Type: Article

References (34)

1. Haffajee AD, Socransky SS. Microbial etiological agents of destructive periodontal diseases. Periodontol 2000 1994;5:78-111.
2. Teng YT. Protective and destructive immunity in the periodontium: Part 1 - innate and humoral immunity and the periodontium. J Dent Res 2006;85:198-208.
3. Teng YT. Protective and destructive immunity in the periodontium: Part 2 - T-cell-mediated immunity in the periodontium. J Dent Res 2006;85:209-219.
4. Shibata S. A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 2000;120:849-862.
5. Classen-Houben D, Schuster D, Da Cunha T et al. Selective inhibition of 11beta-hydroxysteroid dehydrogenase 1 by 18alpha-glycyrrhetinic acid but not 18beta-glycyrrhetinic acid. J Steroid Biochem Mol Biol 2009;113:248-252.
6. Abe M, Akbar F, Hasebe A, Horiike N, Onji M. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J Gastroenterol 2003;38:962-967.
7. Kang OH, Kim JA, Choi YA et al. Inhibition of interleukin-8 production in the human colonic epithelial cell line HT-29 by 18 beta-glycyrrhetinic acid. Int J Mol Med 2005;15:981-985.
8. Ferrer E. Emerging therapeutic strategies for chronic inflammatory diseases. Drug News Perspect 2006;19:353-358.
9. Sasaki H, Okamatsu Y, Kawai T, Kent R, Taubman M, Stashenko P. The interleukin-10 knockout mouse is highly susceptible to Porphyromonas gingivalis-induced alveolar bone loss. J Periodontal Res 2004;39:432-441.
10. Sasaki H, Suzuki N, Kent R Jr, Kawashima N, Takeda J, Stashenko P. T cell response mediated by myeloid cell-derived IL-12 is responsible for Porphyromonas gingivalis-induced periodontitis in IL-10-deficient mice. J Immunol 2008;180:6193-6198.
11. Sasaki H, Hou L, Belani A et al. IL-10, but not IL-4, suppresses infection-stimulated bone resorption in vivo. J Immunol 2000;165:3626-3630.
12. Okamatsu Y, Kim D, Battaglino R, Sasaki H, Spate U, Stashenko P. MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. J Immunol 2004;173:2084-2090.
13. Jorgensen C, Travaglio-Encinoza A, Bologna C, D'Angeac AD, Reme T, Sany J. Human mucosyl lymphocyte marker expression in synovial fluid lymphocytes of patient with rheumatoid arthritis. J Rheumatol 1994;21:1602-1607.
14. Kawai T, Matsuyama T, Hosokawa Y et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006;169:987-998.
15. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001;15:61-78.
16. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 1995;270:9558-9563.
17. Blackwell TS, Christman JW. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol 1997;17:3-9.
18. Lee SY, Reichlin A, Santana A, Sokol KA, Nussenzweig MC, Choi Y. TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival. Immunity 1997;7:703-713.
19. Hawiger J. Innate immunity and inflammation: a transcriptional paradigm. Immunol Res 2001;23:99-109.
20. Wang XC, Jobin C, Allen JB, Roberts WL, Jaffe GJ. Suppression of NF-kappaB-dependent proinflammatory gene expression in human RPE cells by a proteasome inhibitor. Invest Ophthalmol Vis Sci 1999;40:477-486.
21. Rogler G, Gelbmann CM, Vogl D et al. Differential activation of cytokine secretion in primary human colonic fibroblast/myofibroblast cultures. Scand J Gastroenterol 2001;36:389-398.
22. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997;3:1285-1289.
23. Ishijima M, Ezura Y, Tsuji K et al. Osteopontin is associated with nuclear factor kappaB gene expression during tail-suspension-induced bone loss. Exp Cell Res 2006;312:3075-3083.
24. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 2006;25:6680-6684.
25. Yip KH, Zheng MH, Feng HT, Steer JH, Joyce DA, Xu J. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity. J Bone Miner Res 2004;19:1905-1916.
26. Collantes E, Valle Blazquez M, Mazorra V, Macho A, Aranda E, Munoz E. Nuclear factor-kappa B activity in T cells from patients with rheumatic diseases: a preliminary report. Ann Rheum Dis 1998;57:738-741.
27. Gjertsson I, Hultgren OH, Collins LV, Pettersson S, Tarkowski A. Impact of transcription factors AP-1 and NF-kappaB on the outcome of experimental Staphylococcus aureus arthritis and sepsis. Microbes Infect 2001;3:527-534.
28. Xiao G, Rabson AB, Young W, Qing G, Qu Z. Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev 2006;17:281-293.
29. Roman-Blas JA, Jimenez SA. Targeting NF-kappaB: a promising molecular therapy in inflammatory arthritis. Int Rev Immunol 2008;27:351-374.
30. Hardy R, Rabbitt EH, Filer A et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. Ann Rheum Dis 2008;67:1204-1210.
31. Haas CS, Creighton CJ, Pi X et al. Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum 2006;54:047-060.
32. Chisaka H, Johnstone JF, Premyslova M, Manduch Z, Challis JR. Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells. J Soc Gynecol Investig 2005;12:303-309.
33. Lamhamedi-Cherradi SE, Zheng S, Hilliard BA et al. Transcriptional regulation of type I diabetes by NF-kappa B. J Immunol 2003;171:4886-4892.
34. Kotelevtsev Y, Brown RW, Fleming S et al. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 1999;103:683-689.